Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBI-1214 in Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106Phase 1Recruiting
- Sponsor
- Cartography Biosciences
- Start
- Jan 2026
- Primary completion
- Apr 2029
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB21 in colorectal cancer (CRC), sponsored by Cartography Biosciences. Primary endpoints: Safety and tolerability of CBI-1214 at 48 months and Maximum Tolerated Dose and/or Optimum Biological Dose at 48 months. Started Jan 2026; status: recruiting.
02
Drugs
CB21
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07321106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321106.